Abstract
Botulinum toxins are nowadays the gold standard for treatment focal dystonia and some segments of the body in generalized dystonia. These compounds were first used by ophthalmologist in patients with strabismus but later on, they were widely spread in neurological indications especially dystonia.
References
Jabbari B. History of Botulinum Toxin: Treatment in Movement Disorders. Tremor Other Hyperkinet Mov (N Y). 2016;6:394. http://dx.doi.org/10.7916/D81836S1
Truong D, Dressler D, Hallet M. Manual of botulinum toxin therapy. Cambridge University Press 2009. 4th printing 2012. Chapter 3.
Simpson D, Hallet M, Ashman E, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(9):1818-26. http://dx.doi.org/10.1212/WNL.0000000000002560
Dressler D. Botulinum toxin for treatment of dystonia. Eur J Neurol. 2010 Jul;17(Suppl 1):88-96. http://dx.doi.org/10.1111/j.1468-1331.2010.03058.x
Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm (Vienna). 2013;120(2):275-90. http://dx.doi.org/10.1007/s00702-012-0893-9
Evidente VG, Truong D, Jankovic J, Comella CL, Grafe S, Hanschmann A. IncobotulinumtoxinA (Xeomin(R)) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014;346(1-2):116-20. http://dx.doi.org/10.1016/j.jns.2014.08.004
Dressler D, Tacik P, Saberi FA. Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects. J Neural Transm (Vienna). 2015;122(2):297-300. http://dx.doi.org/10.1007/s00702-014-1253-8
Wissel J, Bensmail D, Ferreira J. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity. Neurology Wissel J, Bensmail D, Ferreira J, M2017;88(14):1-8.
Jankovic J. Medical treatment of dystonia. Mov Disord. 2013;28(7):1001-12. http://dx.doi.org/10.1002/mds.25552
Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 20131;67:94-114. http://dx.doi.org/10.1016/j.toxicon.2012.12.004
Colosimo C, Tiple D, Berardelli A. Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res. 2012 22(4):265-273.
Truong D, Comella C, Fernandez HH, Ondo WG. Dysport-Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008;14(5):407-14.
Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011;26(8):1521-28. http://dx.doi.org/10.1002/mds.23658
Kollewe K, Mohammadi B, Kohler S, Pickenbrock H, Dengler R, Dressler D. Blepharospasm: long-term treatment with either Botox(R), Xeomin(R) or Dysport(R). J Neural Transm (Vienna). 2015;122(3):427-31. http://dx.doi.org/10.1007/s00702-014-1278-z.
Greenen C, Consky E, Ashby P. Localizing muscles for botu linum toxin treatment of focal hand dystonia. Can J Neurol Sci.1996;23(3):194-97.
Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord.2005;20(7):783-91. http://dx.doi.org/10.1002/mds.20403
Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999.22;53(7):1439-46.
Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S, U.S. XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308(1-2):103-09.
Wu Ch, Xue F, Cjang W, et al. Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia. SpringerPlus. 2016; 5:1292. http://dx.doi.org/10.1186/s40064-016-2967-x
Truong DD, Bhidayasiri R. Botulinum toxin therapy of laryn-geal muscle hyperactivity syndromes: comparing different botulinum toxin preparations. Eur J Neurol. 2006;13(Suppl 1):36-41.
Fulmer SL, Merati AL, Blumin JH. Efficacy of laryngeal botulinum toxin injection: comparison of two techniques. Laryngoscope. 2011;121(9):1924-28. http://dx.doi.org/10.1002/lary.21966
Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, et al. Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst Rev. 2005 25;(1):CD004899. http://dx.doi.org/10.1002/14651858.CD004899.pub2
Yoshimura DM, Aminoff MJ, Tami TA, Scott AB. Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve. 1992;15(9):1045-49. http://dx.doi.org/10.1002/mus.880150909
Defazio G, Abbruzzese G, Girlanda P, Vacca L, Curra A, De Salvia R, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 2002 Mar;59(3):418-420.
Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, de Haan RJ, Speelman JD. Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry. 2007;78(3):264-70. http://dx.doi.org/10.1136/jnnp.2003.034702
Albanese A, Abbruzzese G, Dressler D, et al. Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol. 2015; 262(10):2201-13. http://dx.doi.org/10.1007/s00415-015-7703-x.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.